Fuji Pharma Co., Ltd. (TYO:4554)
1,857.00
-21.00 (-1.12%)
Nov 13, 2026, 3:30 PM JST
Fuji Pharma Cash Flow Statement
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Net Income | 3,155 | 4,000 | 8,276 | 4,399 | 3,723 |
Depreciation & Amortization | 4,207 | 3,965 | 3,680 | 3,023 | 2,745 |
Loss (Gain) From Sale of Assets | 762 | 394 | - | 4 | 1 |
Loss (Gain) From Sale of Investments | 2,000 | - | -3,118 | - | - |
Other Operating Activities | -1,749 | -2,193 | -1,027 | -941 | -1,504 |
Change in Accounts Receivable | -2,528 | 525 | -1,997 | -3,705 | -549 |
Change in Inventory | -1,294 | -3,078 | 1,552 | -3,395 | -3,618 |
Change in Accounts Payable | -895 | 356 | -1,640 | -652 | 447 |
Change in Other Net Operating Assets | 2,516 | 1,832 | -1,575 | 3,184 | -1,903 |
Operating Cash Flow | 6,174 | 5,801 | 4,151 | 1,917 | -658 |
Operating Cash Flow Growth | 6.43% | 39.75% | 116.54% | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Capital Expenditures | -2,092 | -1,981 | -2,778 | -3,327 | -5,097 |
Sale of Property, Plant & Equipment | 5 | 2 | 2 | 10 | 1,383 |
Sale (Purchase) of Intangibles | -1,806 | -1,873 | -1,594 | -570 | -7,326 |
Investment in Securities | - | - | 5,356 | - | - |
Other Investing Activities | 263 | -367 | -2,644 | -1,353 | -231 |
Investing Cash Flow | -3,630 | -4,219 | -1,658 | -5,240 | -11,271 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Short-Term Debt Issued | - | - | 4,000 | 3,000 | 1,300 |
Long-Term Debt Issued | - | 9,987 | - | 2,985 | 7,300 |
Total Debt Issued | - | 9,987 | 4,000 | 5,985 | 8,600 |
Long-Term Debt Repaid | -1,981 | -7,749 | -5,210 | -2,740 | -2,140 |
Net Debt Issued (Repaid) | -1,981 | 2,238 | -1,210 | 3,245 | 6,460 |
Issuance of Common Stock | 3,300 | 210 | 55 | - | - |
Common Dividends Paid | -1,225 | -1,036 | -972 | -899 | -729 |
Other Financing Activities | -523 | -458 | 1,692 | -431 | -637 |
Financing Cash Flow | -429 | 954 | -435 | 1,915 | 5,094 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Foreign Exchange Rate Adjustments | 135 | 123 | 202 | 185 | 183 |
Miscellaneous Cash Flow Adjustments | - | 1 | - | 2 | -1 |
Net Cash Flow | 2,250 | 2,660 | 2,260 | -1,221 | -6,653 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Free Cash Flow | 4,082 | 3,820 | 1,373 | -1,410 | -5,755 |
Free Cash Flow Growth | 6.86% | 178.22% | - | - | - |
Free Cash Flow Margin | 6.54% | 7.39% | 2.98% | -3.45% | -16.25% |
Free Cash Flow Per Share | 160.31 | 156.54 | 56.48 | -58.02 | -236.90 |
Levered Free Cash Flow | 1,881 | 535.5 | 599.13 | -4,258 | -11,724 |
Unlevered Free Cash Flow | 2,131 | 741.75 | 721.63 | -4,182 | -11,676 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Cash Interest Paid | 393 | 327 | 194 | 104 | 82 |
Cash Income Tax Paid | 1,757 | 2,197 | 1,026 | 946 | 1,498 |
Change in Working Capital | -2,201 | -365 | -3,660 | -4,568 | -5,623 |